116 related articles for article (PubMed ID: 6742867)
1. [Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents].
Tsubaki K; Horiuchi A; Kitani T; Taniguchi N; Masaoka T; Shibata H; Yonezawa T; Tsubakio T; Kawagoe H; Shinohara Y
Gan To Kagaku Ryoho; 1984 Jul; 11(7):1420-7. PubMed ID: 6742867
[TBL] [Abstract][Full Text] [Related]
2. [Chronic cardiotoxicity of anthracycline derivatives and possible prevention by coenzyme Q10].
Tajima M
Gan No Rinsho; 1984 Jul; 30(9 Suppl):1211-6. PubMed ID: 6471423
[TBL] [Abstract][Full Text] [Related]
3. [Protective effect of CoQ 10 administration on cardial toxicity in FAC therapy].
Takimoto M; Sakurai T; Kodama K; Yokoi H; Suzuki Y; Enomoto K; Okada N
Gan To Kagaku Ryoho; 1982 Jan; 9(1):116-21. PubMed ID: 7184359
[TBL] [Abstract][Full Text] [Related]
4. [Protective effects of coenzyme Q10 on the adverse reactions of anthracycline antibiotics: using double blind method--with special reference to hair loss].
Akihama T; Nakamoto Y; Shindo T; Nakayama Y; Miura A
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2125-9. PubMed ID: 6354099
[TBL] [Abstract][Full Text] [Related]
5. [Protective effect of coenzyme Q10 in cardiotoxicity induced by adriamycin].
Okuma K; Furuta I; Ota K
Gan To Kagaku Ryoho; 1984 Mar; 11(3):502-8. PubMed ID: 6703724
[TBL] [Abstract][Full Text] [Related]
6. Adriamycin cardiotoxicity: early detection by systolic time interval and possible prevention by coenzyme Q10.
Cortes EP; Gupta M; Chou C; Amin VC; Folkers K
Cancer Treat Rep; 1978 Jun; 62(6):887-91. PubMed ID: 667863
[TBL] [Abstract][Full Text] [Related]
7. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
[TBL] [Abstract][Full Text] [Related]
8. [A late phase II comparative study of idarubicin + cytarabine and daunorubicin + cytarabine in adult patients with acute non-lymphocytic leukemia. Idarubicin Study Group].
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohhashi Y
Gan To Kagaku Ryoho; 1993 Oct; 20(13):1995-2005. PubMed ID: 8215474
[TBL] [Abstract][Full Text] [Related]
9. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates.
Cicero AF; Derosa G; Miconi A; Laghi L; Nascetti S; Gaddi A
Biomed Pharmacother; 2005 Jul; 59(6):312-7. PubMed ID: 15932792
[TBL] [Abstract][Full Text] [Related]
10. Research on coenzyme Q10 in clinical medicine and in immunomodulation.
Folkers K; Wolaniuk A
Drugs Exp Clin Res; 1985; 11(8):539-45. PubMed ID: 3836873
[TBL] [Abstract][Full Text] [Related]
11. Electrocardiographic and hemodynamic effects of coenzyme Q10 in healthy individuals: a double-blind, randomized controlled trial.
Shah SA; Sander S; Cios D; Lipeika J; Kluger J; White CM
Ann Pharmacother; 2007 Mar; 41(3):420-5. PubMed ID: 17341532
[TBL] [Abstract][Full Text] [Related]
12. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure.
Mortensen SA; Vadhanavikit S; Baandrup U; Folkers K
Drugs Exp Clin Res; 1985; 11(8):581-93. PubMed ID: 3836876
[TBL] [Abstract][Full Text] [Related]
13. Reduction in blood viscosity by treatment with coenzyme Q10 in patients with ischemic heart disease.
Kato T; Yoneda S; Kako T; Koketsu M; Hayano I; Fujinami T
Int J Clin Pharmacol Ther Toxicol; 1990 Mar; 28(3):123-6. PubMed ID: 2318549
[TBL] [Abstract][Full Text] [Related]
14. [Cardiotoxicity of anthracycline cytostatic agents--a proposal for routine monitoring and supportive therapy].
Svojgrová M; Slechtová J; Hůla J
Vnitr Lek; 1991 Feb; 37(2):151-9. PubMed ID: 2021075
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of cardiotoxicity in new anthracycline analog ME 2303. ME 2303 Study Group].
Okuma K; Ariyoshi Y; Wakui A; Ogawa M; Furue H; Niitani H; Shimoyama M; Majima H; Taguchi T; Kimura I
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1143-9. PubMed ID: 2053773
[TBL] [Abstract][Full Text] [Related]
17. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
[TBL] [Abstract][Full Text] [Related]
19. [Electrocardiogram analysis of adriamycin cardiotoxicity in 160 cases].
Wang SQ
Zhonghua Zhong Liu Za Zhi; 1991 Jan; 13(1):71-3. PubMed ID: 1889343
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
